AL001
Late-stage / Terminated
completed
completed
CT.gov grounded
A major FTD progranulin program that now functions as an important field-level setback reference rather than an active growth story.
Program overview
- Mechanism
- progranulin elevation
- Modality
- monoclonal antibody
- Phase
- Late-stage / Terminated
- Status
- completed
- Recruitment
- completed
- Confidence
- medium
- Watch priority
- 3
- Last verified
- 20 Apr 2026
Sponsor and trial identifiers
- Sponsor
- Alector
- Trial IDs
- NCT04374136, NCT03987295
ClinicalTrials.gov exact matches: NCT04374136, NCT03987295
Regions and recruitment
United States
Argentina
Australia
Belgium
Canada
France
Germany
Greece
Italy
Netherlands
Portugal
Spain
Sweden
Switzerland
Turkey (Türkiye)
United Kingdom
Indication tags
FTD
progranulin
Milestones and catalysts
- Last milestone
- A meaningful negative reference point inside progranulin-focused FTD development.
- Next expected catalyst
- No near-term active catalyst, but it matters as context for the FTD field.
Related pages
Disease hub
Frontotemporal dementia hub
Disease-specific views with programs, mechanisms, and related context.
Related programs
Each card explains why it is here so you can read the overlap at a glance.
Early / Mid-stage
active
recruiting
Gene-therapy FTD program that helps make the monitor feel like a real neurodegeneration pipeline rather than an Alzheimer's side project.
- Mechanism
- GRN gene replacement
- Modality
- AAV gene therapy
- Next catalyst
- Early safety and biological activity signals in GRN-FTD.
- Last verified
- 20 Apr 2026
Mid-stage
terminated
terminated
FTD program targeting the progranulin pathway through sortilin inhibition.
- Mechanism
- sortilin inhibition / progranulin elevation
- Modality
- monoclonal antibody
- Next catalyst
- Mid-stage readouts and biomarker alignment.
- Last verified
- 20 Apr 2026
Early / Mid-stage
terminated
terminated
A genetically anchored ALS/FTD program whose termination is still important context for anyone taking the pipeline seriously.
- Mechanism
- C9orf72-targeted oligonucleotide
- Modality
- oligonucleotide
- Next catalyst
- No active catalyst, but it remains a useful reference point for C9-directed clinical translation.
- Last verified
- 20 Apr 2026
Approved / Late-stage
active
active, not recruiting
Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.
- Mechanism
- anti-amyloid antibody
- Modality
- monoclonal antibody
- Next catalyst
- Further rollout, label evolution, and follow-up data.
- Last verified
- 20 Apr 2026